Therapeutic Asset Ratings

329 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Spartalizumab Melanoma	SOLTI Breast Cancer Research Group	P3	CCC (53)
Indocyanine Green Melanoma	M.D. Anderson Cancer Center	P1	CCC (53)
Tranexamic Acid Melanoma	University of Aarhus	P3	CCC (52)
Catequentinib Melanoma	Hunan Cancer Hospital	P2	CCC (52)
CIFURTILIMAB Melanoma	Seagen Inc.	P2	CCC (52)
Cobolimab Melanoma	GlaxoSmithKline	P2	CCC (52)
Dostarlimab Melanoma	GlaxoSmithKline	P2	CCC (52)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Melanoma	Emory University	P2	CCC (52)
Leflunomide Melanoma	N.N. Petrov National Medical Research Center of Oncology	P2	CCC (52)
L-LYSINAMIDE, L-LYSYL-L-LYSYL-L-TRYPTOPHYL-L-TRYPTOPHYL-L-LYSYL-L-LYSYL-L-TRYPTOPHYL-.BETA.-PHENYL-L-PHENYLALANYL- Melanoma	Oslo University Hospital	P2	CCC (52)
Mesna Melanoma	James Isaacs, MD	P2	CCC (52)
Niraparib Melanoma	Tempus AI	P2	CCC (52)
SFX-01 (SULFORAPHANE STABILIZED WITH .ALPHA. CYCLODEXTRIN) Melanoma	Eastern Cooperative Oncology Group	P2	CCC (52)
su011248 Melanoma	National Cancer Institute (NCI)	P2	CCC (52)
t3011 Melanoma	ImmVira Pharma Co. Ltd	P2	CCC (52)
Tiragolumab Melanoma	University Medical Center Groningen	P2	CCC (52)
Trastuzumab Emtansine Melanoma	Ascendis Pharma Oncology Division A/S	P2	CCC (52)
Young Til Melanoma	National Cancer Institute (NCI)	P2	CCC (52)
Zimberelimab Melanoma	Diwakar Davar	P2	CCC (52)
Zoladex Melanoma	Novartis Pharmaceuticals	P2	CCC (52)
Decitabine Melanoma	University of Colorado, Denver	P1/2	CCC (52)
Rapamycin Melanoma	National Cancer Institute (NCI)	P1/2	CCC (52)
Vidutolimod Melanoma	National Cancer Institute (NCI)	P2/3	CCC (52)
flt3 ligand Melanoma	Dana-Farber Cancer Institute	P2	CCC (51)
Maat013 Melanoma	Assistance Publique - Hôpitaux de Paris	P2	CCC (51)

Showing 76 to 100 of 329 assets

PreviousPage 4 of 14Next